Showing results (1331-1340 of 1,345) with videos related to

Sort By:
Pageof 135
Nature Communications|July 24, 2023
The OsSGS3-tasiRNA-OsARF3 module orchestrates abiotic-biotic stress response trade-off in riceXueting Gu, Fuyan Si, Zhengxiang Feng, et al.
Nature Chemical Biology|May 24, 2016
Structural analysis of human KDM5B guides histone demethylase inhibitor developmentCatrine Johansson, Srikannathasan Velupillai, Anthony Tumber, et al.
Acta Dermato-Venereologica|January 27, 2022
Local Hyperthermia Versus Cryotherapy for Treatment of Plantar Warts: A Prospective Multi-centre Non-randomized Concurrent Controlled Clinical TrialWei Huo, Ya-Li Gao, Hong-Yi Wang, et al.
Hepatology (Baltimore, Md.)|May 23, 2015
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transitionZhi-Chao Wang, Qiang Gao, Jie-Yi Shi, et al.
JAMA Neurology|January 21, 2025
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical TrialYunyun Xiong, Xia Meng, Aoming Jin, et al.
Oncogene|May 29, 2025
Macrophage activation determines muscle wasting in pancreatic cancerChia-Jung Chang, Po-Hsien Huang, Szu-Ying Chen, et al.
The Journal of Clinical Investigation|October 16, 2023
SPTAN1/NUMB axis senses cell density to restrain cell growth and oncogenesis through Hippo signalingDongxue Su, Yuxi Li, Weiji Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2024
Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trialLingyun Sun, Yun Xu, Nan Chen, et al.
Cell Chemical Biology|March 7, 2017
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma CellsAnthony Tumber, Andrea Nuzzi, Edward S Hookway, et al.
Signal Transduction and Targeted Therapy|April 2, 2024
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trialQiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, et al.
Pageof 135